|
This "Information for Clinicians" section of the Azixa™ (verubulin, MPC‑6827) GBM Clinical Trials website is intended primarily for the use of healthcare professionals.
For location and contact information, click the following links to be directed to the clinicaltrials.gov page for additional information.
Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme (NCT01285414)
MPC-6827 for Recurrent Glioblastoma Multiforme (NCT00892931)
|